Recently Approved KCC Clinical Trials

08F.126 :    Breast

Purpose:  To determine the disease-free survival of patients (defined as invasive disease-free survival (IFDS) with lymph node positive and high risk lymph node negative breast cancer randomized to treatment with either doxorubicin/cyclophosphamide plus placebo followed by paclitaxel (AC + Placebo > T + Placebo) or the same chemotherapy regimen plus bevacizumab.

Title:  A Double Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer

08D.85 :    Hematologic Malignancies

Title:  A Two Step Approach To Matched-Sibling Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematological Malignancies

08F.263 :    Leukemia

Purpose:  • To determine if early treatment with chemoimmunotherapy comprising fludarabine phosphate and rituximab extends the time to second treatment in patients with genetically high-risk (unmutated IgVH), asymptomatic, previously untreated chronic lymphocytic leukemia (CLL). • To determine the time to disease progression that would warrant second treatment. • To determine overall survival.

Title:  A Phase III Intergroup CLL Study of Asymptomatic Patients with Untreated Chronic Lymphocytic Leukemia Randomized To Early Intervention Versus Observation with Later Treatment in the High risk Genetic Subset with IGVh Unmutated Disease (CALGB 10501)

08F.291 :    Prostate

Purpose:  To formally assess the strategy of active surveillance (with treatment as needed) for low risk, early stage prostate cancer. The strategy will be compared to the strategy of treating patients with radiation or surgery.

Title:  A Phase III Study of Active Surveillance Therapy Against Radical Treatment in Patients Diagnosed With Favourable Risk Prostate Cancer (START)